EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis

Arabella Buchmann iD, Lukas Pirpamer iD, Daniela Pinter iD, Margarete Voortman, Birgit Helmlinger iD, Alexander Pichler iD, Aleksandra Maleska Maceski iD, Pascal Benkert iD, Gerhard Bachmaier iD, Stefan Ropele iD, Markus Reindl iD, David Leppert iD und 3 weitere

European Journal of Neurology · 2023

DOI: 10.1111/ene.15742 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Arabella Buchmann und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Multiple Sclerosis, Central Nervous System Diseases, Neurodegenerative Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Serum neurofilament light chain (sNfL) is a promising biomarker of neuroaxonal damage in persons with multiple sclerosis (pwMS). In cross‐sectional studies, sNfL has been associated with disease activity and brain magnetic resonance imaging (MRI) changes; however, it is still unclear to what extent in particular high sNfL levels impact on subsequent disease evolution. Methods sNfL was quantified by an ultrasensitive single molecule array (Simoa) in 199 pwMS (median age = 34.2 years, 64.3% female) and 49 controls. All pwMS underwent 3‐T MRI to assess global and compartmental normalized brain volumes, T2‐lesion load, and cortical mean thickness. Follow‐up data and serum samples were available in 144 pwMS (median follow‐up time = 3.8 years). Linear and binary logistic models were used to estimate the independent contribution of sNfL for changes in MRI and Expanded Disability Status Scale (EDSS). Age‐corrected sNfL z ‐scores from a normative database of healthy controls were used for sensitivity analyses.

Results

High sNfL levels at baseline were associated with atrophy measures of the whole brain (standardized beta coefficient βj = −0.352, p < 0.001), white matter ( βj = −0.229, p = 0.007), thalamus ( βj = −0.372, p = 0.004), and putamen ( βj = −1.687, p = 0.012). pwMS with high levels of sNfL at baseline and follow‐up had a greater risk of EDSS worsening ( p = 0.007).

Conclusions

Already single time point elevation of sNfL has a distinct effect on brain volume changes over a short‐term period, and repeated high levels of sNfL indicate accumulating physical disability. Serial assessment of sNfL may provide added value in the clinical management of pwMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisCentral Nervous System DiseasesNeurodegenerative DiseasesHumansFemaleAdultMaleCross-Sectional StudiesIntermediate FilamentsBrainBiomarkersNeurofilament ProteinsAtrophy

Stichwörter der Autor:innen

atrophydisabilitymultiple sclerosisneurodegenerationneurofilament

Substanzen

BiomarkersNeurofilament Proteins

Autor:innen und Institutionen

  • Department of Neurology, Medical University of Graz, Graz, Austria.
  • Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.
  • Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
  • Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
  • Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Division of Neuroradiology, Vascular and Interventional Radiology, Medical University of Graz, Graz, Austria.

ORCID-Profile: Arabella Buchmann, Lukas Pirpamer, Daniela Pinter, Birgit Helmlinger, Alexander Pichler, Aleksandra Maleska Maceski, Pascal Benkert, Gerhard Bachmaier, Stefan Ropele, Markus Reindl, David Leppert, Christian Enzinger, Michael Khalil

Zitieren

APA

Buchmann, A., Pirpamer, L., Pinter, D., Voortman, M., Helmlinger, B., Pichler, A., Maceski, A. M., Benkert, P., Bachmaier, G., Ropele, S., Reindl, M., Leppert, D., Kuhle, J., Enzinger, C., & Khalil, M. (2023). High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.15742

Vancouver

Buchmann A, Pirpamer L, Pinter D, Voortman M, Helmlinger B, Pichler A, et al. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. European Journal of Neurology. 2023. doi:10.1111/ene.15742

BibTeX
@article{Buchmann2023,
  author = {Buchmann, Arabella and Pirpamer, Lukas and Pinter, Daniela and Voortman, Margarete and Helmlinger, Birgit and Pichler, Alexander and Maceski, Aleksandra Maleska and Benkert, Pascal and Bachmaier, Gerhard and Ropele, Stefan and Reindl, Markus and Leppert, David and Kuhle, Jens and Enzinger, Christian and Khalil, Michael},
  title = {High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15742}
}
Kostenlos starten →